Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Alex A. Adjei

adjei-alex
Country

United States of America

Address
Mayo Clinic
Rochester, MN

Alex A. Adjei is a Consultant in Oncology, Professor of Oncology and Professor of Pharmacology at Mayo Clinic and Mayo College of Medicine, in Rochester, MN. He oversees oncology drug development as well as lung cancer research and treatment across all 3 Mayo Clinic sites, and is co-Leader of the Developmental Therapeutics program at Mayo Cancer Center.

Dr Adjei has served on a number of US National Cancer Institute (NCI) committees. From 2007 to 2013, he was Chair of the NIH Study Section NCRR Clinical Research Review Committee, reviewing CTSAs. From 2010 – 2014, he was a Member of the Clinical Oncology Study Section (CONC), and from 2013-2017, he was a member of NCI IRG Subcommittee A, reviewing Cancer Centers. He is currently co-chair of the Thoracic Malignancies Steering Committee of NCI. He has served on various committees of professional societies. He was the President of the Minorities in Cancer Research Council of AACR and a member of the Board of Directors of IASLC and is currently Faculty Coordinator for Developmental Therapeutics and member of the Gender Medicine Task Force of ESMO.  Dr Adjei is serving on the Committee on Diagnosing and Treating Adult Cancers of the US National Academies of Sciences, Engineering and Medicine, tasked with providing a report on this topic to the US government (Social Security Administration). He is the Editor-in-Chief of the Journal of Thoracic Oncology and JTO Clinical and Research Report.

Dr Adjei’s research is focused on experimental therapeutics and clinical drug development. He received the first American Society of Clinical Oncology Drug Development Research Professorship 2012-2017, in recognition of his mentorship and his work in cancer drug development. He also received the inaugural IASLC Adi  F. Gazdar Merit Award for Distinguished Service in Lung Cancer, in 2020. He has authored 290 publications dealing primarily with preclinical pharmacology and phase I trials as well as novel therapies for lung cancer.

Last update: February 2021

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings